Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

CD4CAR T Cell Therapy for the Treatment of Patients with Relapsed or Refractory CD4 Positive CMML

Trial Status: temporarily closed to accrual

This phase I trial tests the safety, side effects, best dose, and effectiveness of CD4CAR T cell therapy in treating patients with CD4 positive chronic myelomonocytic leukemia (CMML) that has come back after a period of improvement (relapsed) or has not responded to previous treatment (refractory). CD4 positive CMML is a blood cancer that affects white blood cells that express the protein CD4. Chimeric antigen receptor (CAR) T-cell therapy is a type of treatment in which a patient's T cells (a type of immune system cell) are changed in the laboratory so they will attack cancer cells. T cells are taken from a patient’s blood. Then the gene for a special receptor that binds to a certain protein, such as CD4, on the patient’s cancer cells is added to the T cells in the laboratory. The special receptor is called a CAR. Large numbers of the CAR T cells are grown in the laboratory and given to the patient by infusion for treatment of certain cancers. The CD4CAR T cell therapy is designed to bind to and eliminate cells, including cancer cells that have this protein. CD4CAR T cell therapy may be safe, tolerable and/or effective in treating patients with CD4 positive relapsed or refractory CMML.